Phase 1/2 Randomized Study of the Immunogenicity, Safety, and Tolerability of a Respiratory Syncytial Virus Prefusion F Vaccine in Adults With Concomitant Inactivated Influenza Vaccine

Ann R Falsey, Edward E Walsh, Daniel A Scott, Alejandra Gurtman, Agnieszka Zareba, Kathrin U Jansen, William C Gruber, Philip R Dormitzer, Kena A Swanson, Qin Jiang, Emily Gomme, David Cooper, Beate Schmoele-Thoma, Ann R Falsey, Edward E Walsh, Daniel A Scott, Alejandra Gurtman, Agnieszka Zareba, Kathrin U Jansen, William C Gruber, Philip R Dormitzer, Kena A Swanson, Qin Jiang, Emily Gomme, David Cooper, Beate Schmoele-Thoma

Abstract

Background: Respiratory syncytial virus (RSV) causes substantial morbidity and mortality in older adults and adults with comorbidities. An effective vaccine is needed. An investigational bivalent prefusion F vaccine (RSVpreF) was assessed in healthy adults.

Methods: This phase 1/2 study randomized adults 18-85 years old to receive placebo or 60, 120, or 240 µg RSVpreF (with or without aluminum hydroxide) alone or concomitantly with seasonal inactivated influenza vaccine (SIIV). Safety and immunogenicity were assessed.

Results: In older adults, reactogenicity events were predominantly mild or moderate among RSVpreF recipients; adverse events through 1 month postvaccination were similar across formulations. Coadministration with SIIV did not appear to affect safety among younger or older adults. All RSVpreF formulations with or without concomitant SIIV elicited robust RSV serum-neutralizing responses in adults aged 50-85 years 1 month postvaccination. Neutralizing titers 1 and 12 months postvaccination were 6.9-14.9 and 2.9-4.5 times, respectively, those before vaccination. SIIV immune responses trended lower when coadministered with RSVpreF.

Conclusions: RSVpreF formulations administered alone or with SIIV were well tolerated and highly immunogenic in older adults, supporting the potential for RSVpreF to protect older adults from RSV disease.

Clinical trials registration: NCT03529773.

Keywords: F protein; immunogenicity; older adults; respiratory syncytial virus; safety; vaccine.

© The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America.

Figures

Figure 1.
Figure 1.
Disposition of participants 50–85 years of age in the sentinel (A) and expanded (B) cohorts. Participants who did not receive seasonal inactivated influenza vaccine (SIIV) concomitantly with the respiratory syncytial virus (RSV) vaccine received it 1 month later. aOne participant randomized to the 60-µg bivalent RSV prefusion F vaccine (RSVpreF) + SIIV group did not receive vaccination. bOne participant randomized to the 120-µg RSVpreF + SIIV group was instead administered RSVpreF 240 µg + aluminum hydroxide + SIIV; this participant is included in the population to which the participant was randomized. Abbreviations: AE, adverse event; Al(OH)3, aluminum hydroxide; f/u, follow-up; PV1, post–vaccination 1; RSV, respiratory syncytial virus; RSVpreF, bivalent respiratory syncytial virus prefusion F vaccine; SIIV, seasonal inactivated influenza vaccine.
Figure 2.
Figure 2.
Percentages of expanded cohort participants reporting individual local reactions (A) or systemic events (B) by severity within 14 days postvaccination. Total number of participants = 40–43 per group. 60 = 60 µg bivalent respiratory syncytial virus prefusion F vaccine (RSVpreF); 120 = 120 µg RSVpreF; 240 = 240 µg RSVpreF. Abbreviations: A, aluminum hydroxide; P, placebo; RSVpreF, bivalent respiratory syncytial virus prefusion F vaccine; S, seasonal inactivated influenza vaccine.
Figure 3.
Figure 3.
Respiratory syncytial virus (RSV) neutralizing geometric mean titers before and 1 month post–vaccination 1 for RSV subgroups A and B among expanded cohort participants aged 18–49 years (A) and 65–85 years (B). Neutralizing titer geometric mean fold rises from prevaccination to 1 month postvaccination are indicated above each pair of bars. Total number of participants: 38–41 per group (18–49 years) and 38–43 per group (65–85 years). Abbreviations: Al(OH)3, aluminum hydroxide; GMFR, geometric mean fold rise; GMT, geometric mean titer; m, month; RSV, respiratory syncytial virus; SIIV, seasonal inactivated influenza vaccine.
Figure 4.
Figure 4.
Respiratory syncytial virus (RSV) neutralizing titer geometric mean fold rises through 12 months post–vaccination 1 compared with prevaccination for RSV subgroups A and B in participants aged 18–49 years (A) and 65–85 years (B) in the expanded cohort. Abbreviations: Al(OH)3, aluminum hydroxide; GMFR, geometric mean fold rise; RSV, respiratory syncytial virus; RSVpreF, bivalent respiratory syncytial virus prefusion F vaccine; SIIV, seasonal inactivated influenza vaccine.
Figure 5.
Figure 5.
Hemagglutination inhibition (HAI) geometric mean titers to A/H3N2/Singapore (A), A/H1N1/Michigan (B), B/Colorado (C), and B/Phuket (D) at 1 month after seasonal inactivated influenza vaccine (SIIV) in participants aged 18–49 and 65–85 years receiving either SIIV concomitantly with bivalent respiratory syncytial virus prefusion F vaccine (RSVpreF) (RSVpreF + SIIV) or SIIV 1 month after RSVpreF (SIIV alone) in the expanded cohort (evaluable influenza immunogenicity population). Total number of participants = 31–41 per group. Geometric mean ratios at 1 month after SIIV for concomitant (RSVpreF + SIIV) to sequential (SIIV alone) administration are shown above each bar. Participants 18–49 years of age received quadrivalent SIIV containing A/H3N2/Singapore, A/H1N1/Michigan, B/Colorado, and B/Phuket; participants 65–85 years of age received high-dose trivalent SIIV containing A/H3N2/Singapore, A/H1N1/Michigan, and B/Colorado. Abbreviations: Al(OH)3, aluminum hydroxide; GMR, geometric mean ratio; GMT, geometric mean titer; HAI, hemagglutination inhibition; RSVpreF, bivalent respiratory syncytial virus prefusion F vaccine; SIIV, seasonal inactivated influenza vaccine.
Figure 6.
Figure 6.
Seasonal inactivated influenza vaccine (SIIV) neutralizing geometric mean titers (GMTs) (A/H3N2/Singapore) and hemagglutination inhibition (HAI) GMTs (A/H3N2/Singapore, A/H1N1/Michigan, B/Colorado, B/Phuket) at 1 month after SIIV in participants aged 18–49 years (A) and 65–85 years (B) in the expanded cohort (evaluable influenza immunogenicity population). Total number of participants = 34–41 per group. Geometric mean ratios at 1 month after SIIV for bivalent respiratory syncytial virus prefusion F vaccine (RSVpreF) + SIIV to SIIV alone (ie, 1 month after placebo), to SIIV after RSVpreF, and to pooled SIIV after RSVpreF and SIIV alone are shown above each bar. Participants 18–49 years of age received quadrivalent SIIV containing A/H3N2/Singapore, A/H1N1/Michigan, B/Colorado, and B/Phuket; participants 65–85 years of age received high-dose trivalent SIIV containing A/H3N2/Singapore, A/H1N1/Michigan, and B/Colorado. Abbreviations: Al(OH)3, aluminum hydroxide; GMR, geometric mean ratio; GMT, geometric mean titer; HAI, hemagglutination inhibition; NT, neutralization titer; RSVpreF, bivalent respiratory syncytial virus prefusion F vaccine; SIIV, seasonal inactivated influenza vaccine.

References

    1. Li Y, Johnson EK, Shi T, et al. . National burden estimates of hospitalisations for acute lower respiratory infections due to respiratory syncytial virus in young children in 2019 among 58 countries: a modelling study. Lancet Respir Med 2021; 9:175–85.
    1. Walsh EE. Respiratory syncytial virus infection: an illness for all ages. Clin Chest Med 2017; 38:29–36.
    1. Falsey AR, Hennessey PA, Formica MA, Cox C, Walsh EE.. Respiratory syncytial virus infection in elderly and high-risk adults. N Engl J Med 2005; 352:1749–59.
    1. Falsey AR, McElhaney JE, Beran J, et al. . Respiratory syncytial virus and other respiratory viral infections in older adults with moderate to severe influenza-like illness. J Infect Dis 2014; 209:1873–81.
    1. Walsh EE, Peterson DR, Kalkanoglu AE, Lee FE, Falsey AR.. Viral shedding and immune responses to respiratory syncytial virus infection in older adults. J Infect Dis 2013; 207:1424–32.
    1. Sundaram ME, Meece JK, Sifakis F, Gasser RA Jr, Belongia EA.. Medically attended respiratory syncytial virus infections in adults aged ≥50 years: clinical characteristics and outcomes. Clin Infect Dis 2014; 58:342–9.
    1. Yoon JG, Noh JY, Choi WS, et al. . Clinical characteristics and disease burden of respiratory syncytial virus infection among hospitalized adults. Sci Rep 2020; 10:12106.
    1. Wyffels V, Kariburyo F, Gavart S, Fleischhackl R, Yuce H.. A real-world analysis of patient characteristics and predictors of hospitalization among US Medicare beneficiaries with respiratory syncytial virus infection. Adv Ther 2020; 37:1203–17.
    1. Cusi MG, Martorelli B, Di Genova G, Terrosi C, Campoccia G, Correale P.. Age related changes in T cell mediated immune response and effector memory to respiratory syncytial virus (RSV) in healthy subjects. Immun Ageing 2010; 7:14.
    1. Walsh EE, Falsey AR.. Humoral and mucosal immunity in protection from natural respiratory syncytial virus infection in adults. J Infect Dis 2004; 190:373–8.
    1. Domachowske JB, Anderson EJ, Goldstein M.. The future of respiratory syncytial virus disease prevention and treatment. Infect Dis Ther 2021; 10:47–60.
    1. Boyoglu-Barnum S, Chirkova T, Anderson LJ.. Biology of infection and disease pathogenesis to guide RSV vaccine development. Front Immunol 2019; 10:1675.
    1. Aranda SS, Polack FP.. Prevention of pediatric respiratory syncytial virus lower respiratory tract illness: perspectives for the next decade. Front Immunol 2019; 10:1006.
    1. Aliprantis AO, Shaw CA, Griffin P, et al. . A phase 1, randomized, placebo-controlled study to evaluate the safety and immunogenicity of an mRNA-based RSV prefusion F protein vaccine in healthy younger and older adults. Hum Vaccin Immunother 2021; 17:1248–61.
    1. Johnson PR, Collins PL.. The fusion glycoproteins of human respiratory syncytial virus of subgroups A and B: sequence conservation provides a structural basis for antigenic relatedness. J Gen Virol 1988; 69:2623–8.
    1. McLellan JS. Neutralizing epitopes on the respiratory syncytial virus fusion glycoprotein. Curr Opin Virol 2015; 11:70–5.
    1. Calder LJ, Gonzalez-Reyes L, Garcia-Barreno B, et al. . Electron microscopy of the human respiratory syncytial virus fusion protein and complexes that it forms with monoclonal antibodies. Virology 2000; 271:122–31.
    1. Ngwuta JO, Chen M, Modjarrad K, et al. . Prefusion F-specific antibodies determine the magnitude of RSV neutralizing activity in human sera. Sci Transl Med 2015; 7:309ra162.
    1. Falloon J, Yu J, Esser MT, et al. . An adjuvanted, postfusion F protein-based vaccine did not prevent respiratory syncytial virus illness in older adults. J Infect Dis 2017; 216:1362–70.
    1. Madhi SA, Polack FP, Piedra PA, et al. . Respiratory syncytial virus vaccination during pregnancy and effects in infants. N Engl J Med 2020; 383:426–39.
    1. Crank MC, Ruckwardt TJ, Chen M, et al. . A proof of concept for structure-based vaccine design targeting RSV in humans. Science 2019; 365:505–9.
    1. Sanofi Pasteur Inc. FLUZONE quadrivalent full prescribing information. Swiftwater, PA: Sanofi Pasteur Inc, 2018.
    1. Sanofi Pasteur Inc. FLUZONE high-dose full prescribing information. Swiftwater, PA: Sanofi Pasteur Inc, 2018.
    1. Hall CB, Walsh EE, Schnabel KC, et al. . Occurrence of groups A and B of respiratory syncytial virus over 15 years: associated epidemiologic and clinical characteristics in hospitalized and ambulatory children. J Infect Dis 1990; 162:1283–90.
    1. Ruckwardt TJ, Morabito KM, Phung E, et al. . Safety, tolerability, and immunogenicity of the respiratory syncytial virus prefusion F subunit vaccine DS-Cav1: a phase 1, randomised, open-label, dose-escalation clinical trial. Lancet Respir Med 2021; 9:1111–20.
    1. Beran J, Lickliter JD, Schwarz TF, et al. . Safety and immunogenicity of 3 formulations of an investigational respiratory syncytial virus vaccine in nonpregnant women: results from 2 phase 2 trials. J Infect Dis 2018; 217:1616–25.
    1. Gustafson CE, Kim C, Weyand CM, Goronzy JJ.. Influence of immune aging on vaccine responses. J Allergy Clin Immunol 2020; 145:1309–21.

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner